A Phase IB/II Study of Lirilumab with Azacytidine in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blockade of inhibitory killer-cell immunoglobulin receptor (KIR) receptors induces augmented NK-cell mediated tumor cell lysis (Romagne F et al., Blood 2009). Hypomethylating agents (HMAs) possess anti-leukemia activity, and increase MHC II expression, cancer antigen exposure in solid and hematologic malignancies, and interferon-gamma signature. KIR-receptor blockade by lirilumab (KIR2DL1/2/3-antibody) may improve responses to HMAs.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) developing in persons exposed to DNA-damaging agents for a prior cancer are often referred to as treatment- or therapy-related myeloid neoplasms (t-MN)[1,2]. t-MN constitute approximately 10-20% of all cases of AML and MDS[3], a proportion that may increase in the future with an increasing prevalence of cancer survivors[4,5]. Hematopoietic cell transplants (HCT) use high doses of drugs and/or ionizing radiations and can also lead to t-MN[6,7].
Source: Leukemia Research - Category: Hematology Authors: Source Type: research
The glycoprotein CD56, also known as a neural cell adhesion molecule (NCAM), plays an important role in normal physiological functions.   It is expressed in low levels in normal cells such as neurons, glia, skeletal muscle and natural killer cells. It is highly expressed on a variety of cancerous cells including those of neuroblastoma, small-cell lung cancer, and multiple myeloma.  In neuroblastoma, patients undergo a very aggress ive standard of care regimen that results in a high mortality rate.  Many neuroblastomas have increased expression of CD56, which represents a possible therapeutic target for these...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Publication date: June 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 6Author(s): Raja Pramanik, Anudishi Tyagi, Anita Chopra, Akash Kumar, Sreenivas Vishnubhatla, Sameer BakhshiAbstractBackgroundThe purpose of our study was to evaluate the clinical, cytogenetic, and molecular features, and survival outcomes in patients with acute myeloid leukemia (AML) with myeloid sarcoma (MS) and compare them with patients with AML without MS.Patients and MethodsThis was a retrospective analysis of de novo pediatric AML patients with or without MS diagnosed at our cancer center between June 2003 and June 2016....
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Our analysis provided no convincing evidence for an increased risk of death from a range of hematolymphopoietic cancers in workers exposed to high or medium levels of ELF magnetic fields. However, we observed an increased risk of acute myeloid leukaemia in workers exposed to high levels for a longer duration. Observed risks are in line with meta-analysed previous reports on ELF-MF exposure and AML risk, with a summary relative risk of 1.21 (95%CI 1.08-1.37). PMID: 29587222 [PubMed - as supplied by publisher]
Source: Environmental Research - Category: Environmental Health Authors: Tags: Environ Res Source Type: research
AbstractResistance to apoptosis is one of the hallmarks of cancer and members of the B-cell lymphoma 2 (BCL-2) family of proteins are central regulators of apoptosis. Many cancers become resistant to chemotherapy and apoptosis by up-regulating BCL-2 and other family members, making these proteins attractive targets for cancer therapy. Venetoclax is an orally administered, small-molecule apoptosis stimulant that targets BCL-2 proteins by acting as a BCL-2 homology domain 3 (BH3) mimetic. The drug is approved in the USA and EU as a monotherapy for the for the treatment of certain patients with chronic lymphocytic leukemia (C...
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION Cognitive impairment can affect daily functioning, quality of life, and capacity to work in patients with cancer and those in remission. Consequently, cognitive assessment is now an important and necessary part of a comprehensive oncological care plan. Cancer-related cognitive impairment might be due to the direct effects of the cancer itself, nonspecific factors, or comorbid conditions that are independent of the disease and/or due to the adverse effects of the treatment or combination of treatments given for the disease. The prevalence and extent of cognitive impairment associated with cancer is recognized but...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Cognition Current Issue Neuro oncology Neurology Review cancer chemotherapy cognitive impairment neuropsychological assessment treatment Source Type: research
Conclusion This study did not support associations between night-shift work and hematological cancers.byTalibov M, Pukkala E, Martinsen JI, Tryggvadottir L, Weiderpass E, Hansen J. doi:10.5271/sjweh.3704
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Tags: Original article Source Type: research
Conclusion This study did not support associations between night-shift work and hematological cancers. PMID: 29323398 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Authors: Tags: Scand J Work Environ Health Source Type: research
Conclusion CLAG plus IM was well tolerated, with encouraging signs of activity in patients with poor-risk AML. Micro-Abstract Given the lack of standard salvage chemotherapy regimen for relapsed or refractory (RR) acute myeloid leukemia (AML), a phase 2 clinical study of cladribine, cytarabine, G-CSF (CLAG) regimen in combination with imatinib mesylate (IM) in patients with RR-AML was conducted at the Moffitt Cancer Center. Between August 2009 and April 2011, 38 patients were treated and the overall response rate was 37% with a median overall survival of 11.1 month. Among responders, 8/14 patients proceeded to allogeneic h...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Patients with AML had a higher sepsis incidence and higher mortality rates overall, especially in relation to stem-cell transplant recipients and those with other types of cancer. Clinical trials are needed to determine whether early intervention or treatment in specialized centers could improve outcomes and reduce costs of care, particularly in the management of serious complications such as sepsis. Micro-Abstract We reviewed outcomes of patients with acute myeloid leukemia (AML) and sepsis in Texas. AML patients (0.25% of > 2 million discharges) had a higher incidence of sepsis (16% vs. 4%) and of sepsis-re...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Hematology | Leukemia | Lymphoma | Myeloma | Study